Amicus Therapeutics Inc (FOLD)
10.56
-0.10
(-0.94%)
USD |
NASDAQ |
Apr 16, 16:00
10.56
0.00 (0.00%)
After-Hours: 17:45
Amicus Therapeutics Enterprise Value: 3.250B for April 15, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 15, 2024 | 3.250B |
| April 12, 2024 | 3.256B |
| April 11, 2024 | 3.416B |
| April 10, 2024 | 3.431B |
| April 09, 2024 | 3.572B |
| April 08, 2024 | 3.528B |
| April 05, 2024 | 3.564B |
| April 04, 2024 | 3.487B |
| April 03, 2024 | 3.460B |
| April 02, 2024 | 3.460B |
| April 01, 2024 | 3.572B |
| March 28, 2024 | 3.581B |
| March 27, 2024 | 3.605B |
| March 26, 2024 | 3.478B |
| March 25, 2024 | 3.510B |
| March 22, 2024 | 3.507B |
| March 21, 2024 | 3.555B |
| March 20, 2024 | 3.646B |
| March 19, 2024 | 3.599B |
| March 18, 2024 | 3.522B |
| March 15, 2024 | 3.493B |
| March 14, 2024 | 3.510B |
| March 13, 2024 | 3.590B |
| March 12, 2024 | 3.584B |
| March 11, 2024 | 3.685B |
| Date | Value |
|---|---|
| March 08, 2024 | 3.735B |
| March 07, 2024 | 3.732B |
| March 06, 2024 | 3.823B |
| March 05, 2024 | 4.045B |
| March 04, 2024 | 4.078B |
| March 01, 2024 | 4.027B |
| February 29, 2024 | 3.888B |
| February 28, 2024 | 3.927B |
| February 27, 2024 | 4.193B |
| February 26, 2024 | 4.172B |
| February 23, 2024 | 4.098B |
| February 22, 2024 | 4.060B |
| February 21, 2024 | 4.107B |
| February 20, 2024 | 4.148B |
| February 16, 2024 | 4.166B |
| February 15, 2024 | 4.237B |
| February 14, 2024 | 3.995B |
| February 13, 2024 | 3.883B |
| February 12, 2024 | 4.144B |
| February 09, 2024 | 4.080B |
| February 08, 2024 | 4.015B |
| February 07, 2024 | 3.918B |
| February 06, 2024 | 3.913B |
| February 05, 2024 | 3.830B |
| February 02, 2024 | 3.754B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.402B
Minimum
Mar 12 2020
6.366B
Maximum
Dec 22 2020
3.131B
Average
3.041B
Median
Enterprise Value Benchmarks
| TG Therapeutics Inc | 2.058B |
| Geron Corp | 1.632B |
| Vanda Pharmaceuticals Inc | -154.66M |
| Fate Therapeutics Inc | 245.52M |
| Editas Medicine Inc | 174.32M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -33.84M |
| Revenue (Quarterly) | 115.08M |
| Total Expenses (Quarterly) | 118.77M |
| EPS Diluted (Quarterly) | -0.11 |
| Gross Profit Margin (Quarterly) | 90.16% |
| Profit Margin (Quarterly) | -29.41% |
| Earnings Yield | -4.83% |
| Normalized Earnings Yield | -4.381 |